Healthcare Global Enterprises · NSE: HCG · BSE: 539787

Q3 FY25 results · Oct–Dec 2024

Healthcare Global Enterprises reported revenue from operations of ₹557.55 crore (up 18.7% from Q3 FY24) and net profit of ₹7.75 crore (up 125.9% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY25	Q3 FY24	YoY	Q2 FY25	QoQ
Revenue from operations	557.55	469.87	+18.7%	553.54	+0.7%
Other income	5.66	6.07	−6.8%	11.13	−49.1%
Total income	563.21	475.94	+18.3%	564.67	−0.3%
Profit before share of associates & JVs and tax	(4.20)	11.07	Turned loss	27.68	Turned loss
Share of profit/(loss) of associates & JVs	0.90	(0.01)		(0.03)
Net profit for the period	7.75	3.43	+125.9%	20.68	−62.5%
Attributable to shareholders of the company	6.98	5.70	+22.5%	17.99	−61.2%
EPS, basic (₹)	0.50	0.41	+22.2%	1.29	−61.2%
Net margin (%)	1.4	0.7		3.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY25	Q3 FY24	YoY	Q2 FY25	QoQ
Revenue from operations	311.67	267.21	+16.6%	306.67	+1.6%
Other income	6.13	5.52	+11.1%	10.24	−40.1%
Total income	317.80	272.73	+16.5%	316.91	+0.3%
Profit before tax	(36.38)	14.95	Turned loss	20.99	Turned loss
Net profit for the period	(37.33)	8.33	Turned loss	16.03	Turned loss
EPS, basic (₹)	(2.68)	0.60	Turned loss	1.15	Turned loss
Net margin (%)	-12.0	3.1		5.2

Consolidated

Filed with BSE: 14 Feb 2025, 16:37 IST
Board meeting: 14 Feb 2025
Period: 01 Oct 2024 to 31 Dec 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 14 Feb 2025, 16:37 IST
Board meeting: 14 Feb 2025
Period: 01 Oct 2024 to 31 Dec 2024
Review status: Unaudited
Source: XBRL filing on BSE